MedTrace Logo

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

NCT06199713 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.

Conditions

  • Melanoma
  • Melanoma Stage III
  • Melanoma Stage IV
  • Unresectable Melanoma

Interventions

DIAGNOSTIC_TEST

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

research scan 3-4 weeks after start of immunotherapy

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Vincent Ma, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2027-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06199713 on ClinicalTrials.gov